Managing neuromuscular pain in cats can be challenging due to the paucity of acceptable medications. Despite gabapentin being the most commonly used drug to treat pain in cats, few clinical studies that specifically examine its action in cats exist. This study evaluated the pharmacokinetics of intravenous, oral, and transdermal administration of gabapentin in a limited group of cats. Results indicate that transdermal gabapentin has poor bioavailability. In addition, the pharmacokinetics of gabapentin when administered twice daily were not significantly different than when the drug was administered once daily, suggesting that accumulation is not a significant factor with this medication. Optimum plasma drug concentration is still not known and needs further investigation, but this study suggests that a dosage of 10 mg/kg q12h is insufficient for maintaining plasma levels that have been associated with efficacy in other species.